引入细胞和基因疗法产品的生物类似竞争
Brian Canter1, Sabine Sussman1, Stephen Colvill1
1Duke University Margolis Institute for Health Policy, Durham, NC 27708, USA.
Journal of law and the biosciences
|July 16, 2024
概括
开发生物类似细胞和基因疗法 (CGTs) 面临重大障碍. 基因疗法在生物相似性方面比细胞疗法更有前途,但制造和监管方面的挑战仍然存在.
科学领域:
- 生物技术是生物技术.
- 制药科学 制药科学
- 监管科学 监管科学
背景情况:
- 细胞和基因疗法 (CGTs) 代表了医学领域快速发展的前沿领域.
- 确保患者获得和负担得起这些复杂的治疗方法是一个日益关注的问题.
- 生物相似药物竞争的潜力,以解决成本和获取障碍,正在进行早期调查.
研究的目的:
- 分析开发生物类似版本CGT的可行性.
- 在CGT市场中确定未来生物类似药竞争的关键挑战和机会.
- 提供专家驱动的监管,制造,知识产权和市场规模方面的观点.
主要方法:
- 基于专家采访的定性分析.
- 在CGT中探索生物相似性的监管途径.
- 制造复杂性和知识产权景观的评估.
- 讨论市场动态和影响生物类似药物采用的经济因素.
主要成果:
- 在满足CGT的"高度相似性"监管标准方面存在重大挑战.
- 基因疗法被认为比细胞疗法更容易接受生物类似的发展.
- 制造业的复杂性,知识产权和市场规模构成了巨大的障碍.
- 最近的法律决定可能会为与专利相关的障碍提供一些缓解.
结论:
- 对CGT的生物相似开发是复杂的,基因疗法是一个更可行的途径.
- 克服制造业标准化,成本和监管障碍至关重要.
- 知识产权和市场规模的考虑将对CGT生物类似药的成功产生重大影响.
相关概念视频
Bioequivalence: Overview
975
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
975
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
Hybridoma Technology
14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509


